Angela DeMichele, MD, MSCE
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
Make an appointmentCall 215-615-5858
Penn Medicine Provider

About me

  • Co-Leader, Breast Cancer Research Program
  • Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence
  • Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence

Dr. DeMichele specializes in developing new therapies for breast cancer, neoadjuvant therapy  and preventing breast cancer recurrence.

Co-Chair of the ECOG/ACRIN Cooperative Group Breast Committee; Chair, Trial Operations Working Group, I-SPY Consortium; Member of the NCI Breast Cancer Steering Committee

Education and training

  • Medical School: Washington University School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

254 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
she has been my dr for 10 years. i would never want anyone else.
October 2025
dr. demichele is thorough, explains clearly, empathetic, kind, and knowledgeable.
September 2025
her expertise provided me great guidance. she was also very invested and engaged in my appointment.
September 2025
angie demichele is an excellent, caring physician and i have been treated by her for over 9 years.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. DeMichele is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Chislock EM, Pan TC, Pant D, Chen Y, Woodfield G, Graves J, Lawrence-Paul MR, Belka GK, Wang J, Bayne L, Blanchard T, Smith M, Ji X, Shih NNC, Soucier-Ernst D, Goodman N, Nivar I, Goodspeed B, DeLuca S, Ndicu J, Clark C, Langer M, William Stavropoulos S, DeMuth W, Morschauser A, Murphy W, Nayak A, Feldman M, Clark A, Yu L, Judge K, Bornheimer S, Pletcher CH Jr, Moore JS, DeMichele A, Chodosh LA. DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer , NPJ Breast Cancer : 2025

Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL. Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. , Clin Cancer Res: 2025

Thomas A, Rhoads A, Mayer EL, O'Reilly S, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, Conway KM, Ignatiadis M, Kalinsky K, DeMichele A, Romitti PA. Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021. , NPJ Breast Cancer: 2025

Hennessy, M. A., Gatsonis, C., Jacene, H., Connolly, R. M., Burnette, B. L., Stringer-Reasor, E. M., Romanoff, J., Taurone, A., O'Sullivan, C. C., Le-Petross, H. T., Stearns, V., Fowler, A. M., Tang, S., Sepulveda, K. A., DeMichele, A. M., Mankoff, D. A., Wolff, A. C. EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial) , Future Oncology : 2025

DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nature Medicine: 2025

Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL. Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study. , Clin Cancer Res: 2025

Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial , Ann Surg Oncol.: 2025

Mukhtar, R. A., Dimitroff, K., Yau, C., Chien, A. J., Connolly, E. P., Howard-McNatt, M., Rao, R., Ladores, V., Golshan, M., Sauder, C. A., Ahmed, K., Lancaster, R., Fox, J., Gutnik, L., Lee, M. C., Tchou, J., Prionas, N., Arciero, C. A., Reyna, C., Kuerer, H., Switalla, K., Taunk, N., Tuttle, T. M., Moran, M. S., Postlewait, L. M., Perlmutter, J., DeMichele, A., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Esserman, L. J., Van't Veer, L., Boughey, J. C. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial , Annals of surgical oncology: 2025

Villacampa, G., Pascual, T., Tarantino, P., Cortés, J., Perez-García, J., Llombart-Cussac, A., Conte, P., Mancino, M., Guarneri, V., Dieci, M. V., Waks, A. G., Schettini, F., Brasó-Maristany, F., Griguolo, G., de Castro, B. A., Reboredo, C., Antolín, S., Bueno-Muiño, C., Echavarría, I., López-Tarruella, S., Massarrah, T., Monte-Millán, M. D., Martin, M., Buckingham, W., Parker, J. S., Vivancos, A., Polyak, K., Filho, O. M., Wolff, A. C., DeMichele, A., Tung, N. M., Perou, C. M., Paré, L., Villagrasa, P., Prat, A., Tolaney, S. M. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis , Lancet Oncology: 2025

Kaur, M., Dimitroff, K., Boughey, J. C., Esserman, L. J., Yau, C., Tchou, J., Quirarte, A., Lee, M. C., Howard-McNatt, M. M., Switalla, K., Kuerer, H., Sauder, C., Postlewait, L. M., Arciero, C., Rao, R., Wallace, A., Reyna, C., Ahmed, K., Gutnik, L., Taunk, N., Perlmutter, J., DeMichele, A., Yee, D., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Rudra, S., Pohlmann, P., Ewing, C., Wong, J., Alvarado, M., Jaskowiak, N., Prionas, N., Golshan, M., Piltin, M. A., Olopade, O. I., Mukhtar, R. A. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial , Ann Surg Oncol : 2025